JP2013517233A - 抗感染ピリド（１，２−ａ）ピリミジン - Google Patents
抗感染ピリド（１，２−ａ）ピリミジン Download PDFInfo
- Publication number
- JP2013517233A JP2013517233A JP2012548380A JP2012548380A JP2013517233A JP 2013517233 A JP2013517233 A JP 2013517233A JP 2012548380 A JP2012548380 A JP 2012548380A JP 2012548380 A JP2012548380 A JP 2012548380A JP 2013517233 A JP2013517233 A JP 2013517233A
- Authority
- JP
- Japan
- Prior art keywords
- nmr
- mhz
- pyrido
- cdcl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 COC(C1=NC(Nc(cc2)cc3c2[n]cn3)=C2C(*)=O)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc(cc2)cc3c2[n]cn3)=C2C(*)=O)=CC=CN1C2=O 0.000 description 3
- JWTCFERBVZTPOA-UHFFFAOYSA-N COC(C1=NC(Nc2ccccc2)=C2C=S)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc2ccccc2)=C2C=S)=CC=CN1C2=O JWTCFERBVZTPOA-UHFFFAOYSA-N 0.000 description 2
- UGXXHPWNGPZCGF-UHFFFAOYSA-N CC(C)C(C(OCC1=C(Nc(cc2)cc3c2nccc3)N=C(C(OC)=CC=C2)N2C1=O)=O)N Chemical compound CC(C)C(C(OCC1=C(Nc(cc2)cc3c2nccc3)N=C(C(OC)=CC=C2)N2C1=O)=O)N UGXXHPWNGPZCGF-UHFFFAOYSA-N 0.000 description 1
- XQTRADXQBPOLSQ-UHFFFAOYSA-N CC(C)C(NCC1=C(Nc2cc3cccnc3cc2)N=C(C(OC)=CC=C2)N2C1=O)=O Chemical compound CC(C)C(NCC1=C(Nc2cc3cccnc3cc2)N=C(C(OC)=CC=C2)N2C1=O)=O XQTRADXQBPOLSQ-UHFFFAOYSA-N 0.000 description 1
- NSWZUGMEZJHNER-UHFFFAOYSA-N CC(C)C(OCC1=C(Nc(cc2)cc3c2nccc3)N=C(C(OC)=CC=C2)N2C1=O)=O Chemical compound CC(C)C(OCC1=C(Nc(cc2)cc3c2nccc3)N=C(C(OC)=CC=C2)N2C1=O)=O NSWZUGMEZJHNER-UHFFFAOYSA-N 0.000 description 1
- XANBAVHQUXJJAO-UHFFFAOYSA-N CC(C)COC(NCC1=C(Nc(cc2)cc3c2nccc3)N=C(C(OC)=CC=C2)N2C1=O)=O Chemical compound CC(C)COC(NCC1=C(Nc(cc2)cc3c2nccc3)N=C(C(OC)=CC=C2)N2C1=O)=O XANBAVHQUXJJAO-UHFFFAOYSA-N 0.000 description 1
- LQYYIVPNJQXFCI-UHFFFAOYSA-N CC(C)OC(NCC1=C(Nc(cc2)cc3c2nccc3)N=C(C(OC)=CC=C2)N2C1=O)=O Chemical compound CC(C)OC(NCC1=C(Nc(cc2)cc3c2nccc3)N=C(C(OC)=CC=C2)N2C1=O)=O LQYYIVPNJQXFCI-UHFFFAOYSA-N 0.000 description 1
- NCEBORCUSSYINC-UHFFFAOYSA-N CC(C1=NC(Cl)=C2C(OC)=O)=CC=CN1C2=O Chemical compound CC(C1=NC(Cl)=C2C(OC)=O)=CC=CN1C2=O NCEBORCUSSYINC-UHFFFAOYSA-N 0.000 description 1
- VRVKXMSBNPBYSV-UHFFFAOYSA-N CC(C1=NC(Nc2cc(C(OC)=O)ccc2)=C2C(O)=O)=CC=CN1C2=O Chemical compound CC(C1=NC(Nc2cc(C(OC)=O)ccc2)=C2C(O)=O)=CC=CN1C2=O VRVKXMSBNPBYSV-UHFFFAOYSA-N 0.000 description 1
- UKXLOPQUQKBEKW-UHFFFAOYSA-N CC(C1=NC(Nc2ccccc2)=C2C(O)=O)=CC=CN1C2=O Chemical compound CC(C1=NC(Nc2ccccc2)=C2C(O)=O)=CC=CN1C2=O UKXLOPQUQKBEKW-UHFFFAOYSA-N 0.000 description 1
- NAUNSMBMRBNQPI-UHFFFAOYSA-N CC(C=CN12)=CC1=NC(Nc(cc1)cc3c1[nH]cc3)=C(CO)C2=O Chemical compound CC(C=CN12)=CC1=NC(Nc(cc1)cc3c1[nH]cc3)=C(CO)C2=O NAUNSMBMRBNQPI-UHFFFAOYSA-N 0.000 description 1
- VFQMOZDSFIZXBB-UHFFFAOYSA-N CC(C=CN12)=CC1=NC(Nc(cc1)cc3c1[n](C)nc3)=C(CO)C2=O Chemical compound CC(C=CN12)=CC1=NC(Nc(cc1)cc3c1[n](C)nc3)=C(CO)C2=O VFQMOZDSFIZXBB-UHFFFAOYSA-N 0.000 description 1
- RGIJDIXOFXVUQP-UHFFFAOYSA-N CC([n](ccc1c2)c1ccc2NC(N=C1N2C=CC=C1OC)=C(CO)C2=O)=O Chemical compound CC([n](ccc1c2)c1ccc2NC(N=C1N2C=CC=C1OC)=C(CO)C2=O)=O RGIJDIXOFXVUQP-UHFFFAOYSA-N 0.000 description 1
- IMHYYLOTCYSLJV-UHFFFAOYSA-N CC1=C(Nc2ccccc2)N=C(C(OC)=CC=C2)N2C1=O Chemical compound CC1=C(Nc2ccccc2)N=C(C(OC)=CC=C2)N2C1=O IMHYYLOTCYSLJV-UHFFFAOYSA-N 0.000 description 1
- KZDHTEHBHTWMIC-UHFFFAOYSA-N CC1=CC=CN2C1=NC(O)=CC2=O Chemical compound CC1=CC=CN2C1=NC(O)=CC2=O KZDHTEHBHTWMIC-UHFFFAOYSA-N 0.000 description 1
- YJLTUOQYZLQVIJ-UHFFFAOYSA-N CCOC(C(C(N(CCCC1)C1=N1)=O)=C1OS(c1ccc(C)cc1)(=O)=O)=O Chemical compound CCOC(C(C(N(CCCC1)C1=N1)=O)=C1OS(c1ccc(C)cc1)(=O)=O)=O YJLTUOQYZLQVIJ-UHFFFAOYSA-N 0.000 description 1
- XWHWMOZATFMLEA-UHFFFAOYSA-N CCOC(C1=C(Nc(cc2)cc3c2[nH]nc3)N=C(C=C(C)C=C2)N2C1=O)=O Chemical compound CCOC(C1=C(Nc(cc2)cc3c2[nH]nc3)N=C(C=C(C)C=C2)N2C1=O)=O XWHWMOZATFMLEA-UHFFFAOYSA-N 0.000 description 1
- SNORBAALHDCGKY-UHFFFAOYSA-N CCOC(C1=C(Nc(cc2)ccc2O)N=C(CCCC2)N2C1=O)=O Chemical compound CCOC(C1=C(Nc(cc2)ccc2O)N=C(CCCC2)N2C1=O)=O SNORBAALHDCGKY-UHFFFAOYSA-N 0.000 description 1
- ZXNPJNYRDHFJBV-UHFFFAOYSA-N CCOC(C1=CN=C(C(C)=CC=C2)N2C1=O)=O Chemical compound CCOC(C1=CN=C(C(C)=CC=C2)N2C1=O)=O ZXNPJNYRDHFJBV-UHFFFAOYSA-N 0.000 description 1
- GHQULFZPHSBAGH-UHFFFAOYSA-N CN(C)c1cnc(NC(N=C2N3C=CC=C2OC)=C(CO)C3=O)nc1 Chemical compound CN(C)c1cnc(NC(N=C2N3C=CC=C2OC)=C(CO)C3=O)nc1 GHQULFZPHSBAGH-UHFFFAOYSA-N 0.000 description 1
- ZYIKNNLYNZEQHN-UHFFFAOYSA-N COC(C1=NC(Cl)=C2CO)=CC=CN1C2=O Chemical compound COC(C1=NC(Cl)=C2CO)=CC=CN1C2=O ZYIKNNLYNZEQHN-UHFFFAOYSA-N 0.000 description 1
- DUNKHCKETMNRDH-UHFFFAOYSA-N COC(C1=NC(Cl)=C2COC3OCCCC3)=CC=CN1C2=O Chemical compound COC(C1=NC(Cl)=C2COC3OCCCC3)=CC=CN1C2=O DUNKHCKETMNRDH-UHFFFAOYSA-N 0.000 description 1
- VFAOKESNMOMTAV-UHFFFAOYSA-N COC(C1=NC(NCc(cc2)ccc2N(CC2)CCN2c2ccccc2)=C2C=O)=CC=CN1C2=O Chemical compound COC(C1=NC(NCc(cc2)ccc2N(CC2)CCN2c2ccccc2)=C2C=O)=CC=CN1C2=O VFAOKESNMOMTAV-UHFFFAOYSA-N 0.000 description 1
- PDJKKHBSKGVIHP-UHFFFAOYSA-N COC(C1=NC(Nc(cc2)cc3c2OCO3)=C2CO)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc(cc2)cc3c2OCO3)=C2CO)=CC=CN1C2=O PDJKKHBSKGVIHP-UHFFFAOYSA-N 0.000 description 1
- NVYNBRVPLVKHEM-UHFFFAOYSA-N COC(C1=NC(Nc(cc2)cc3c2[nH]c(C(O)=O)c3)=C2CO)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc(cc2)cc3c2[nH]c(C(O)=O)c3)=C2CO)=CC=CN1C2=O NVYNBRVPLVKHEM-UHFFFAOYSA-N 0.000 description 1
- YALIHALHVFAULH-UHFFFAOYSA-N COC(C1=NC(Nc(cc2)cc3c2nccc3)=C2CNC(c3ccccc3)=O)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc(cc2)cc3c2nccc3)=C2CNC(c3ccccc3)=O)=CC=CN1C2=O YALIHALHVFAULH-UHFFFAOYSA-N 0.000 description 1
- KTZLFNREBHIUGF-UHFFFAOYSA-N COC(C1=NC(Nc(cc2)cc3c2nccc3)=C2CNCc3ccccc3)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc(cc2)cc3c2nccc3)=C2CNCc3ccccc3)=CC=CN1C2=O KTZLFNREBHIUGF-UHFFFAOYSA-N 0.000 description 1
- VFGDQHMYGSTMSD-UHFFFAOYSA-N COC(C1=NC(Nc(cc2F)ccc2F)=C2COC3OCCCC3)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc(cc2F)ccc2F)=C2COC3OCCCC3)=CC=CN1C2=O VFGDQHMYGSTMSD-UHFFFAOYSA-N 0.000 description 1
- GCIKNOHNEVUIKI-UHFFFAOYSA-N COC(C1=NC(Nc2c3[nH]ccc3ccc2)=C2CO)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc2c3[nH]ccc3ccc2)=C2CO)=CC=CN1C2=O GCIKNOHNEVUIKI-UHFFFAOYSA-N 0.000 description 1
- OGCINNHHKLRWKU-UHFFFAOYSA-N COC(C1=NC(Nc2cc3cccnc3cc2)=C2C(F)=O)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc2cc3cccnc3cc2)=C2C(F)=O)=CC=CN1C2=O OGCINNHHKLRWKU-UHFFFAOYSA-N 0.000 description 1
- VWWZJWUKMXBFLJ-UHFFFAOYSA-N COC(C1=NC(Nc2cc3cccnc3cc2)=C2c3ncc[s]3)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc2cc3cccnc3cc2)=C2c3ncc[s]3)=CC=CN1C2=O VWWZJWUKMXBFLJ-UHFFFAOYSA-N 0.000 description 1
- DXJZHBVPESAABK-UHFFFAOYSA-N COC(C1=NC(Nc2cccc(N(CC3)CCN3c(cc3)ccc3F)c2)=C2CO)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc2cccc(N(CC3)CCN3c(cc3)ccc3F)c2)=C2CO)=CC=CN1C2=O DXJZHBVPESAABK-UHFFFAOYSA-N 0.000 description 1
- KLPOHHUHVUIJHA-UHFFFAOYSA-N COC(C1=NC(Nc2ccccc2)=C2C=O)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc2ccccc2)=C2C=O)=CC=CN1C2=O KLPOHHUHVUIJHA-UHFFFAOYSA-N 0.000 description 1
- SJFINYCNVDMWNP-UHFFFAOYSA-N COC(C1=NC(Nc2ccccc2)=C2CS)=CC=CN1C2=O Chemical compound COC(C1=NC(Nc2ccccc2)=C2CS)=CC=CN1C2=O SJFINYCNVDMWNP-UHFFFAOYSA-N 0.000 description 1
- LIDPCGZBTBDFNV-UHFFFAOYSA-N Cc(cc1)ccc1Oc(c(Cl)c1)ccc1NC(N=C1N2C=CC=C1OC)=C(CO)C2=O Chemical compound Cc(cc1)ccc1Oc(c(Cl)c1)ccc1NC(N=C1N2C=CC=C1OC)=C(CO)C2=O LIDPCGZBTBDFNV-UHFFFAOYSA-N 0.000 description 1
- DAJMNKBJENYOSH-UHFFFAOYSA-N Cc1nc(ccc(NC(N=C2N3C=CC=C2OC)=C(CO)C3=O)c2)c2[s]1 Chemical compound Cc1nc(ccc(NC(N=C2N3C=CC=C2OC)=C(CO)C3=O)c2)c2[s]1 DAJMNKBJENYOSH-UHFFFAOYSA-N 0.000 description 1
- OCBOOAIIHLARHK-UHFFFAOYSA-N OCC1=C(Nc2cccc(C(F)(F)F)c2)N=C(C=CC=C2)N2C1=O Chemical compound OCC1=C(Nc2cccc(C(F)(F)F)c2)N=C(C=CC=C2)N2C1=O OCBOOAIIHLARHK-UHFFFAOYSA-N 0.000 description 1
- YMOMVOAQMWWQQD-UHFFFAOYSA-N OCC1=C(Nc2cccc(C(O)=O)c2)N=C(C=CC=C2)N2C1=O Chemical compound OCC1=C(Nc2cccc(C(O)=O)c2)N=C(C=CC=C2)N2C1=O YMOMVOAQMWWQQD-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29455210P | 2010-01-13 | 2010-01-13 | |
| US61/294,552 | 2010-01-13 | ||
| PCT/EP2011/000135 WO2011085990A1 (en) | 2010-01-13 | 2011-01-13 | Anti - infective pyrido (1,2 -a) pyrimidines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2013517233A true JP2013517233A (ja) | 2013-05-16 |
Family
ID=43610218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548380A Withdrawn JP2013517233A (ja) | 2010-01-13 | 2011-01-13 | 抗感染ピリド（１，２−ａ）ピリミジン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130012506A1 (pt-PT) |
| EP (1) | EP2523956A1 (pt-PT) |
| JP (1) | JP2013517233A (pt-PT) |
| KR (1) | KR20130088002A (pt-PT) |
| CN (1) | CN102812023A (pt-PT) |
| AU (1) | AU2011206761A1 (pt-PT) |
| BR (1) | BR112012017473A2 (pt-PT) |
| CA (1) | CA2786329A1 (pt-PT) |
| WO (1) | WO2011085990A1 (pt-PT) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014019750B1 (pt) * | 2012-02-10 | 2020-03-03 | F. Hoffmann-La Roche Ag. | Composto, composição farmacêutica e seus usos |
| JP6092264B2 (ja) | 2012-03-01 | 2017-03-08 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋委縮症を処置するための化合物 |
| CA2868026C (en) | 2012-03-23 | 2021-02-16 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| EP3227292B1 (en) * | 2014-12-02 | 2022-03-09 | Alterity Therapeutics Limited | 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS |
| US10668171B2 (en) | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| CN105153151A (zh) * | 2015-08-28 | 2015-12-16 | 张文莲 | 一种嘧啶酮类化合物的合成方法 |
| WO2017100726A1 (en) | 2015-12-10 | 2017-06-15 | Ptc Therapeutics, Inc. | Methods for treatng huntington's disease |
| EP3544435A4 (en) | 2016-11-28 | 2020-11-04 | PTC Therapeutics, Inc. | RNA SPLICE MODULATION PROCESSES |
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2018232039A1 (en) | 2017-06-14 | 2018-12-20 | Ptc Therapeutics, Inc. | Methods for modifying rna splicing |
| CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| WO2019005980A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | METHODS OF TREATING HUNTINGTON'S DISEASE |
| SG11202009212WA (en) | 2018-03-27 | 2020-10-29 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
| EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210042265A (ko) | 2018-06-27 | 2021-04-19 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로사이클릭 및 헤테로아릴 화합물 |
| CN114106000B (zh) * | 2021-12-15 | 2023-11-24 | 中国科学院新疆理化技术研究所 | 一种咪唑并[4,5-d]嘧啶酮三环类衍生物及抗肿瘤用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US4957773A (en) | 1989-02-13 | 1990-09-18 | Syracuse University | Deposition of boron-containing films from decaborane |
| WO2001058876A1 (fr) * | 2000-02-09 | 2001-08-16 | Daiichi Pharmaceutical Co., Ltd. | Agents antibacteriens acidoresistants renfermant des acides pyridonecarboxyliques comme principe actif |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| CN102105470B (zh) * | 2008-06-17 | 2014-06-04 | 韩国巴斯德研究所 | 作为抗结核病药的吡啶并嘧啶化合物 |
| WO2010001366A1 (en) * | 2008-07-04 | 2010-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Piperazines derivatives as proteasome modulators |
-
2011
- 2011-01-13 AU AU2011206761A patent/AU2011206761A1/en not_active Abandoned
- 2011-01-13 KR KR1020127018472A patent/KR20130088002A/ko not_active Application Discontinuation
- 2011-01-13 US US13/518,292 patent/US20130012506A1/en not_active Abandoned
- 2011-01-13 CN CN2011800059743A patent/CN102812023A/zh active Pending
- 2011-01-13 JP JP2012548380A patent/JP2013517233A/ja not_active Withdrawn
- 2011-01-13 BR BR112012017473A patent/BR112012017473A2/pt not_active IP Right Cessation
- 2011-01-13 EP EP11700392A patent/EP2523956A1/en not_active Withdrawn
- 2011-01-13 WO PCT/EP2011/000135 patent/WO2011085990A1/en active Application Filing
- 2011-01-13 CA CA2786329A patent/CA2786329A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2786329A1 (en) | 2011-07-21 |
| WO2011085990A8 (en) | 2012-10-26 |
| WO2011085990A1 (en) | 2011-07-21 |
| KR20130088002A (ko) | 2013-08-07 |
| CN102812023A (zh) | 2012-12-05 |
| EP2523956A1 (en) | 2012-11-21 |
| AU2011206761A1 (en) | 2012-07-12 |
| US20130012506A1 (en) | 2013-01-10 |
| BR112012017473A2 (pt) | 2019-09-24 |
| AU2011206761A2 (en) | 2012-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517233A (ja) | 抗感染ピリド（１，２−ａ）ピリミジン | |
| JP5739329B2 (ja) | 抗結核剤としてのピリドピリミジン化合物 | |
| EP2576540B1 (en) | Heteroaryl compounds and methods of use thereof | |
| CA2568914C (en) | Therapeutic agents, and methods of making and using the same | |
| DK2519522T3 (en) | SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS | |
| US20090156578A1 (en) | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents | |
| CA2658506A1 (en) | Acrylamide derivatives as fab 1 inhibitors | |
| KR20220068243A (ko) | 포스포디에스테라제 억제제 및 용도 | |
| CA3204171A1 (en) | Bicyclic derivatives | |
| JP2006517976A (ja) | 新規化合物 | |
| EP2496577A1 (en) | Imidazopyridine derivatives | |
| JP2023508475A (ja) | 抗菌性キノリン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20140401 |